On February 18, 2026, the FDA announced it would review Moderna's application for its experimental mRNA flu vaccine.
This decision comes after the agency had refused to accept the application just days earlier, surprising many in the medical and financial communities.
The FDA plans to make a decision regarding the flu vaccine by August 5, 2026. If approved, the vaccine could be available for the upcoming influenza season.
Moderna's CEO, Stéphane Bancel, expressed optimism, stating the company looks forward to providing a new option for seniors to protect themselves against the flu.
Moderna's revised application seeks full approval for its flu vaccine for adults aged 50 to 64 and an accelerated approval for individuals aged 65 and up.
The latter approval will require additional post-marketing studies to confirm the vaccine's effectiveness in older adults. This approach comes after a productive meeting with the FDA, during which Moderna addressed concerns raised in the agency's previous refusal.
Following the FDA's announcement, shares of Moderna saw an increase of more than 6%. The company aims to reach breakeven by 2028, with the flu vaccine being a vital part of this strategy.
The successful rollout of the vaccine could help solidify Moderna's position in the broader immunization market.
The FDA had previously criticized the design of Moderna's clinical trials, stating that it did not meet the best-available standards of care in the United States.
The FDA recommended that Moderna use a higher-dose vaccine for older adults as a comparator in its trials. However, Moderna contended that the FDA's rules do not require trials to use the highest-dose vaccine as a standard for comparison. The company also highlighted that the FDA initially indicated that using the standard flu shot was acceptable.
Moderna's ongoing discussions with the FDA and the acceptance of its modified application mark significant progress in the company's efforts to expand its vaccine portfolio.
The outcome of the FDA's review will be closely watched as it could influence future developments in mRNA technology application beyond COVID-19 vaccines.
